



January 29th & January 30th, 2027, Canary Islands

Fundación Canaria de Cáncer de Pulmón

PRELIMINARY PROGRAM

SCIENTIFIC COORDINATORS

Dr. Rosario García Campelo, Complejo Hospitalario Univ. de A Coruña

Dr. Luis Paz-Ares. Hospital Univ. 12 de Octubre. Madrid

Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

Dr. Delvys Rodríguez Abreu. Hospital Univ. Insular, Las Palmas de Gran Canaria

Friday 29th January

08:55 – 09:10 Welcome and official opening

09:10- 09:30 Lecture: In search of the next checkpoint – Why have we failed and where do we look next?

Keynote: Dr. Solange Peters. Univ. Hospital of Lausanne, Switzerland

Chairs: Dr. Delvys Rodríguez Abreu, Hospital Univ. Insular, Las Palmas de Gran Canaria

09:30 – 09:40 Discussion

09:40 – 11:00 SESSION I. Challenging clinical situations

Chairs: Dr. Mohammad Jahanzeb. Florida Atlantic University, USA

Dr. Arsela Prelaj. IRCCS National Cancer Institute Foundation of Milan, Italy

09:40 – 09:50 Case presentation

Dr. Pilar Soto. Hospital Univ. Insular, Las Palmas de Gran Canaria

09:50 – 09:55 Lung cancer in pregnant women.

Dr. Oscar Arrieta Rodríguez. National Cancer Institute. Mexico

09:55 – 10:05 Case presentation

Dr. Anna Estival. Hospital Univ. Insular, Las Palmas de Gran Canaria

10:05 – 10:10 Lung cancer in the young adults

Dr. Narjust Florez. Dana-Farber Cancer Institute, Boston, USA

10:10 – 10:20 Case presentation

Dr. Patricia Iranzo. Hospital Univ. Vall d'Hebron, Barcelona

10:20 – 10:25 Lung cancer in a transplant patient

Dr. Jordi Remon. Institute Gustave Roussy, Paris, France

10:25 – 10:35 Case presentation

Dr. Manuel Fernández Bruno. Complejo Hospitalario Univ. de A Coruña

10:35 – 10:40 Lung cancer in a patient with significant autoimmune disease

Dr. Jarushka Naidoo. Beaumont RCSI Cancer Centre, Dublin, Ireland

10:40 – 11:00 Panel Discussion.

Dr. Mora Guardamagna. Hospital Univ. Dr. Negrín, Las Palmas

Dr. Nuria Mederos. Univ. Hospital of Lausanne, Switzerland

Dr. Martín Lázaro. Hospital Álvaro Cunqueiro, Vigo

Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

11:00 – 11:25 COFFEE BREAK

11:25 – 13:20 SESSION II. Advanced stage driver-positive NSCLC

Chairs: Dr. Rolf Stahel. ETOP IBCSG Partners Foundation, Berne, Switzerland

TBD

11:25 – 11:40 Advanced EGFR-Mutant NSCLC: First-Line Standards for Today and Tomorrow

Dr. Zofia Piotrowska. Mass General Brigham Cancer Institute

11:40 – 11:55 Later-Line Therapy in EGFR-Mutant NSCLC: Overcoming Resistance

Dr. Molly Li. Chinese University of Hong Kong, China

11:55 – 12:10 Targeting EGFR exon 20 insertions & other uncommon EGFR mutations

Dr. Natasha Leighl. Hospital Princess Margaret Cancer Centre, Toronto, Canada

12:10 – 12:20 HER2-Altered NSCLC: Integrating Novel Agents into Clinical Practice

Dr. Jon Zugazagoitia. Hospital Univ. 12 de Octubre, Madrid

12:20 – 12:30 Emerging Strategies for KRAS G12C-Mutant NSCLC

Dr. Alfredo Addeo. Geneva University Hospitals. Switzerland

12:30 – 12:40 Beyond G12C: The Future of KRAS-Mutant NSCLC

Dr. Jair Bar. School of Medicine, Tel Aviv University, Tel Aviv, Israel

12:40 – 13:20 Panel Discussion

Dr. Oscar Juan. Hospital Univ. y Politécnico La Fe, Valencia

Dr. Jesús Corral. Hospital Univ. de Jerez de la Frontera, Cádiz

Dr. Ana Laura Ortega Granados. Hospital Univ. de Jaén, Andalucía

Dr. Dolores Isla. Hospital Univ. Lozano Blesa, Zaragoza

13:20 – 14:30 LUNCH BREAK (Group photo 13:30-13:35)

14:30 – 16:15 SESSION III. Other targets in NSCLC

Chairs: Dr. Rosario García Campelo, Complejo Hospitalario Univ. de A Coruña

Dr. Rafael Rosell. Hospital Univ. Dexeus, Barcelona

14:30 – 14:40 Can We Raise the CROWN Even Further in ALK-Positive NSCLC?

Dr. Benjamin J. Solomon. Peter MacCallum Cancer Centre, Melbourne, Australia

14:40 – 14:55 Focus on fusions in NSCLC: ROS1, RET, and NTRK

Dr. Lorenza Landi. Regina Elena National Cancer Institute, Rome, Italy

14:55 – 15:10 Optimizing Treatment for BRAF- and MET-Altered NSCLC

Dr. Anne-Marie C. Dingemans. Erasmus MC Cancer Institute, Rotterdam, Netherlands

15:10 – 15:20 Understanding and Targeting MTAP Deletions in NSCLC

Dr. Enriqueta Felip. Hospital Univ. Vall d'Hebron, Barcelona

15:20 – 15:30 Surgery for stage IV NSCLC: Who, when and why?

Dr. Isabelle Schmitt-Opitz. Switzerland

15:30 – 15:40 Is SBRT appropriate in oligometastatic NSCLC — and if so, when and how?

Dr. Cecile Le Pechoux. Institute Gustave Roussy, Paris, France

15:40 – 16:20 Panel Discussion

Dr. Antonio Araujo. Hospital Univ. Oporto, Portugal

Dr. Pilar Garrido. Hospital Univ. Ramón y Cajal, Madrid

Dr. Juan Carlos Trujillo Reyes. Hospital de la Santa Creu i Sant Pau. Barcelona

Dr. Javier Martín Ortega. Hospital Univ. Nuestra Señora de la Candelaria. Tenerife

16:20 – 16:30 COFFEE BREAK

16:30 – 18:15 SESSION IV. Targeted therapy in early stage and locally advanced NSCLC

Chairs: Dr. Santiago Ponce. Hospital Univ. 12 de Octubre, Madrid

Dr. Bartomeu Massuti. Hospital General Univ. Dr. Balmis, Alicante

16:30 – 16:45 Targeting EGFR in resectable NSCLC: where do we go from here?

Dr. Pasi Jänne. Dana-Farber Cancer Institute, Boston, USA

16:45 – 16:55 Adjuvant therapy for ALK, RET, and beyond

Dr. Pilar Garrido. Hospital Univ. Ramón y Cajal, Madrid

16:55 – 17:10 Targeted therapy after chemoradiation

Dr. Daniel Tan. National Cancer Centre Singapore

17:10 – 17:20 MRD in early lung cancer

Dr. Luis E. Raez. Memorial Cancer Institute at Memorial Healthcare System, Florida, USA

17:20 – 17:35 Do we need RCT for every setting? Leveraging AI to change clinical research

Dr. Arsela Prelaj. IRCCS National Cancer Institute Foundation of Milan, Italy

17:35 – 18:15 Panel Discussion

TBD

Dr. Reyes Bernabé. Hospital Univ. Virgen del Rocío, Sevilla

Dr. Sergio Vázquez. Hospital Univ. Lucus Augusti, Lugo

Dr. Helena Linardou. Metropolitan Hospital, Athens, Greece

18:15 CLOSING

Saturday 30th January

09:00 Welcome

09:00 – 10:20 SESSION V. Small cell lung cancer

Chairs: Dr. Manuel Domine. IIS-FJD. Oncohealth Institute, Madrid

09:00 – 09:15 Optimizing the integration of T-cell engagers into the current treatment paradigm of SCLC

Dr. Giannis Mountzios. Henry Dunant Hospital Center. Athens, Greece

09:15 – 09:30 Putting the pieces together in SCLC: ADCs, bispecifics, Lurbinectedin, chemo-immunotherapy

Dr. Stephen Liu. Lombardi Cancer Center Georgetown University, Washington, USA

09:30 – 09:40 Evolving role of radiation and radio-ligands in SCLC

Dr. Egbert F. Smit. Leiden University Medical Center, Leiden, Netherlands

09:40 – 10:20 Panel Discussion

Dr. Helena Linardou. Metropolitan Hospital, Athens, Greece

Dr. Joachim Aerts. Pulmonary Medicine Erasmus MC in Rotterdam, Netherlands

Dr. José Manuel Trigo. Hospital HC Marbella, Malaga

Dr. Anne-Marie C. Dingemans. Erasmus MC Cancer Institute, Rotterdam, Netherlands

10:20 - 10:40 COFFEE BREAK

10:40 – 12:05 SESSION VI. Early stage driver negative NSCLC

Chairs: Dr. Jair Bar. School of Medicine, Tel Aviv University, Tel Aviv, Israel

Dr. Enriqueta Felip. Hospital Univ. Vall d'Hebron, Barcelona

10:40 – 10:55 Current state of neoadjuvant and perioperative immunotherapy for NSCLC

Dr. Federico Cappuzzo. Regina Elena National Cancer Institute, Rome, Italy

10:55 – 11:10 What have we improved in the surgical management of lung cancer?

Dr. Diego González Rivas. Shanghai Pulmonary Hospital, China

11:10 – 11:25 How to integrate genomic testing to prove clinical utility in the perioperative scenario?

Dr. David Gandara. University of California Davis, California, USA

11:25 – 12:05 Panel Discussion

Dr. José Ramón Cano. Hospital Univ. Insular, Las Palmas de Gran Canaria

Dr. Cecile Le Pechoux. Institute Gustave Roussy, Paris

Dr. Noemi Reguart. Hospital Clinic Barcelona

Dr. Ignacio Gil Bazo. Hospital Quirónsalud. Zaragoza

12:05 – 13:40 SESSION VII. Advanced driver negative NSCLC.

Chairs: Dr. David Gandara. University of California Davis, California, USA

Dr. Federico Cappuzzo. Regina Elena National Cancer Institute, Rome, Italy

12:05 – 12:20 Bispecifics for NSCLC: Impact or impasse?

Dr. Martin Reck. LungenClinic Grosshansdorf, Hamburg, Germany

12:20 – 12:35 How Best to Integrate ADCs in Driver-Negative NSCLC

Dr. David Carbone. James Thoracic Oncology Center. Ohio, USA

12:35 – 12:50 ADC and new Bispecific developments in China

Dr. Chunxia Su. Shanghai Pulmonary Hospital. China

12:50 - 13:00 Biomarkers for ADCs

Dr. Fred Hirsch. Icahn School of Medicine at Mount Sinai, New York, USA

13:00 – 13:40 Discussion and Q&A

Dr. Enric Carcereny. Hospital Univ. Germans Trías i Pujol, Badalona, Barcelona

Dr. Antonio Calles. Hospital General Univ. Gregorio Marañón, Madrid

Dr. Margarita Majem. Hospital de la Santa Creu i Sant Pau. Barcelona

Dr. Santiago Viteri. UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona

13:40 – 13:45 CLOSING REMARKS